Singular Genomics Systems (OMIC) announced its G4 Sequencing Platform demonstrated compatibility with the 10x Genomics’ (TXG) Chromium Single Cell platform through the 10x Compatible Partner Program. The 10x Genomics Chromium Single Cell platform combines instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Combined with the G4, a powerful, highly versatile benchtop genomic sequencer, users will be able to produce fast, accurate and cost-effective single cell sequencing results.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on OMIC:
- Singular Genomics Joins the 10x Genomics Compatible Partner Program
- Singular Genomics sees Q4 revenue about $700,000, consensus $650,000
- Singular Genomics Reports Instrument Shipments and Preliminary Unaudited Fourth Quarter 2022 Revenue
- Singular Genomics to Present at the 41st Annual J.P. Morgan Healthcare Conference
